LLY•benzinga•
Lilly To Present Results From Phase 3 EMBER-3 Study Of Imlunestrant, An Oral SERD, And Additional Results From Its Breast Cancer Portfolio At The San Antonio Breast Cancer Symposium
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on November 1, 2024 by benzinga